Accumulation of the amyloid-b peptide (Ab) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer's disease. The b-amyloid protein precursor (APP) is cleaved by one of two b-secretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99aa C-terminal fragment (C99). The C99 fragment serves as substrate for g-secretase to generate the 4kD amyloid-b peptide (Ab), which is deposited in the Alzheimer's disease patients' brains. BACE was identified by several groups independently and designated b-site APP cleaving enzyme (BACE). BACE is a transmembrane aspartic protease and co-localizes with APP. BACE2 also cleaves APP at b-site and at a different site within Ab. BACE2 locates on chromosome 21q22.3, the so-called 'Down critical region', suggesting that BACE2 and Ab may also contribute to the pathogenesis of Down syndrome.
Rabbit polyclonal antibodies were raised against peptide sequences corresponding to each of the target proteins.
Both APP antibodies will react with the C99 fragment of APP. These antibodies can be used for detection of APP, BACE and BACE2 by immunoblot at 1-5ug/ml. Anti-APP and Anti-BACE can detect their respective proteins via immunohistochemistry at 2-10ug/ml.
APP, CT (Rb x Hu): 1x25ug
APP, AbNT (Rb x Hu): 1x25ug
BACE, CT (Rb x Hu): 1x25ug
BACE2, NT (Rb x Hu): 1x25ug
Suitable for use in Western Blot and Immunohistochemistry. Other applications not tested.
Western Blot: 1-5ug/ml
Optimal dilutions to be determined by the researcher.
Human brain tissue lysate
Storage and Stability:
May be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.